This chapter describes the elements involved in caring for the pregnant woman with HIV infection, whether the woman was known to be HIV infected before conception or was found to be HIV infected during pregnancy. It is not intended to be a comprehensive discussion of this topic, and an HIV-experienced obstetrician and an HIV specialist should be involved in the management of all HIV-infected pregnant women. For centers that do not have HIV specialists available, experts at the National Perinatal HIV Consultation and Referral Service are available for consultation through the Perinatal HIV Hotline (888-448-8765).
The goals of HIV management during pregnancy are to maintain and support the woman's health, provide optimal antiretroviral treatment (ART) to preserve or restore her immune system and suppress viral replication, and to offer interventions that decrease the risk of perinatal HIV transmission. According to the U.S. Department of Health and Human Services perinatal guidelines, Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States, all HIV-infected pregnant women should be given ART during pregnancy to prevent mother-to-child transmission of HIV, and ART also is recommended for all women for their own health, regardless of pregnancy status (see chapter Reducing Maternal-Infant HIV Transmission).
The first task in caring for an HIV-infected woman who is pregnant or considering pregnancy is to provide counseling that will allow her to make informed reproductive choices. Taking a careful reproductive history and providing preconception counseling should be part of any woman's routine primary care. To make informed choices about pregnancy, the patient needs education and information about the risk of perinatal transmission of HIV, potential complications of pregnancy, continuation or modification (or possibly, initiation) of ART, and the support she will need to optimize maternal and fetal outcomes. See chapter Health Care of HIV-Infected Women Through the Life Cycle for a more detailed discussion of preconception evaluation.
An appropriate ART regimen should be started before pregnancy to attain a stable, maximally suppressed maternal viral load prior to conception. This will support the woman's own health and greatly reduce the risk of HIV transmission either to a fetus or to a sex partner. Antiretroviral (ARV) resistance testing should be performed before ART is initiated. For women who intend to conceive, particular ARVs should be avoided, including those with increased risk of causing teratogenicity (e.g., efavirenz) or metabolic complications such as lactic acidosis (e.g., didanosine and stavudine). see chapter Reducing Maternal-Infant HIV Transmission. It should be noted that most fetal organogenesis occurs in the early weeks of pregnancy, before most women know that they are pregnant. Thus, any medication with potential teratogenicity or fetal toxicity, whether an ARV or another drug, should not be administered to women who intend to become pregnant or may become pregnant. Certain medications (e.g., ribavirin) also should be avoided by male partners of women who may become pregnant.
Folate supplementation to reduce the risk of neural tube defects in the developing fetus should be started at least 1 month before conception, if possible, because the neural tube forms in the early weeks of pregnancy (see below).
Evaluation and Counseling of Pregnant Women
All HIV-infected pregnant women should receive thorough education and counseling about perinatal transmission risks, strategies to reduce those risks, and potential effects of HIV infection or HIV treatment on the course or outcomes of pregnancy.
- The goals of therapy for pregnant women receiving ART, as for all persons being treated for HIV infection, are to suppress the HIV viral load maximally (preferably to undetectable levels) for as long as possible, to improve quality of life, to restore or preserve immune function, and to prevent transmission to sexual (or injection drug equipment-sharing) partners. For pregnant women, an additional, and critical, goal is to reduce the risk of perinatal transmission as much as possible.
- Therapy-associated adverse effects, including hyperglycemia, anemia, and hepatic toxicity, may have a negative effect on maternal and fetal health outcomes. Pregnant women should be advised about possible ARV-related adverse effects and should be monitored regularly for these events.
- HIV-infected women should receive evaluation and appropriate prophylaxis for opportunistic infections (OIs), as well as the vaccinations indicated for persons with HIV infection (see below).
- Some medications, both ARVs and other drugs, may cause fetal anomalies or toxicity when taken during pregnancy. These should be avoided in pregnant women, unless the anticipated benefit outweighs the risk. Consult with an HIV or obstetric specialist, a pharmacist, or the drug labeling information before prescribing medications for pregnant women.
- Options for mode of delivery should be discussed early. The benefits and risks of vaginal vs. cesarean delivery are outlined in the perinatal guidelines. If the HIV viral load is >1,000 copies/mL at 36 weeks of pregnancy, a scheduled cesarean delivery at 38 weeks' gestation is recommended to further reduce the risk of transmission.
Other evaluation and support measures for pregnant women should include the following:
- Screening for other potential maternal health problems, such as diabetes and hypertension
- Maternal nutritional evaluation and support, including initiation of a prenatal multivitamin containing folate (0.4 mg PO QD) to reduce the risk of fetal neural tube defects; for women receiving trimethoprim-sulfamethoxazole, some experts recommend higher folate doses in the first trimester; consult with an HIV-experienced obstetric specialist.
- Screening for psychiatric and neurologic disease
- Counseling about the risks of tobacco smoking; smoking cessation support as indicated (see chapter Smoking Cessation)
- Counseling about the risks of alcohol or drug use and support for discontinuation of these activities as needed
- Intimate partner violence screening
- Review of medications, including over-the-counter and nutritional agents, and discontinuation of medications with the potential for fetal harm
- Immunizations (e.g., influenza, Tdap, hepatitis B) as indicated
- Institution of the standard measures for evaluation and management (e.g., assessment of reproductive and familial genetic history, screening for infectious diseases or sexually transmitted diseases [STDs])
- Planning for maternal-fetal medicine consultation, if desired or indicated
- Selection of effective and appropriate postpartum contraceptive methods, if desired
Comprehensive Care of Pregnant Women with HIV Infection
Comprehensive care is important for pregnant women with HIV infection to achieve a healthy pregnancy and delivery. A multidisciplinary approach is the most effective way to address the medical, psychological, social, and practical challenges. For example, while her medical care is being managed by her obstetrician and an HIV specialist, the pregnant woman may need help from a social worker to find appropriate social services for food, housing, child care, and parenting issues. The pregnant woman may need counseling and psychological support for herself and her partner, as well as referrals for substance abuse and detoxification programs. Peer counselors may be of particular assistance. Some patients may need legal or domestic violence services during and after pregnancy. Cooperation and communication between the obstetrician or nurse/midwife and the primary HIV provider are imperative throughout the pregnancy and early postpartum period. Referral to a maternal-fetal medicine specialist may be needed in complicated obstetric cases.
All pregnancy-related complications seen in HIV-uninfected women, such as hypertensive disorders, ectopic pregnancy, psychiatric illness, multiple gestation, preterm delivery, and STDs, also can occur in HIV-infected women. These problems must be recognized quickly and treated appropriately to avoid life-threatening complications. Ideally, HIV-infected pregnant women are managed by both an experienced obstetrician-gynecologist and an HIV specialist. Communication between these specialists about medications, expectations, and complications is vital for the health and well-being of both mother and baby. If complications occur or abnormalities are detected, they should be evaluated and treated as indicated by the condition, and referral should be made to a maternal-fetal medicine specialist, if possible. Antenatal fetal surveillance and testing to identify fetal abnormalities should be carried out using guidelines established by the American College of Obstetricians and Gynecologists.
The suggested testing and monitoring practices for pregnant women with HIV infection, from the first trimester to labor and delivery, are presented in Tables 1 and 2.
|HIV History||Date of diagnosis||Initial|
|Signs and symptoms||Initial and at every visit|
|Nadir CD4 and current CD4 cell count; HIV viral load||Initial|
|ARV history, including regimen efficacy, toxicity, and ARV resistance||Initial|
|Opportunistic infections and malignancies||Initial and at every visit|
|History of STDs||Initial|
|Adherence||Initial and at every visit|
|Obstetric History||Number of pregnancies; complications and outcomes (GPAL [gravida, para, abortion, living children]); mode of deliveries||Initial|
|History of genetic disorders||Initial|
|Use of ARV prophylaxis during previous pregnancies||Initial|
|HIV status of children||Initial|
|Current Pregnancy||Last menstrual period (LMP)||Initial|
|Pregnancy: intended or not||Initial|
|Contraceptive methods used, if any||Initial|
|Gestational age (can be calculated in a woman with regular menses by counting weeks from LMP)||Initial and at every visit|
|Estimated date of delivery||Initial|
|Signs or symptoms of maternal complications: elevated blood pressure, headache, significant edema, gastrointestinal or genitourinary symptoms, vaginal discharge or bleeding, decreased fetal movement (fetal movement is usually first detected at 18-24 weeks of pregnancy)||Initial and at every visit|
|Screen for depression||Initial|
|Screen for intimate-partner violence||Initial and at every visit|
|General||Vital signs and weight||Initial and at every visit|
|Funduscopy, breast examination||Initial and as indicated|
|Gynecologic/Obstetric (usually performed by the obstetric provider)||Pelvic examination, STD screening, examination for perineal or vaginal lesions (discoloration, condyloma, ulcerative lesions, vaginal discharge), cervical lesions, discharge or bleeding||Initial and as indicated|
|Fundal height, correlating with gestational age (concordant between 18 and 30 weeks)||Every visit starting the second trimester|
|Fetal heart beat and rate: may be audible with Doppler devices as early as 12 weeks||Initial and at every visit|
|Fetal movements and position in third trimester||Every visit starting at 24 weeks|
|Laboratory and Other Studies|
|HIV||HIV antibody test (if not already documented)||Initial|
|HIV viral load and CD4 count (total and percentage); results obtained at 35-36 weeks guide decisions on the mode of delivery||Viral load at initial visit, 2-4 weeks after starting or changing ART, every 4 weeks until undetectable, then at least every 3 months|
CD4 count at initial visit and at least every 3 months
|Genotype if ARV naive or detectable HIV RNA while on ART||Initial and as indicated|
|Cytomegalovirus (CMV) immunoglobulin G (IgG)||Initial|
|G6PD level in appropriate ethnic or racial groups if PCP prophylaxis with dapsone is anticipated||Initial|
|General||Complete blood count (CBC)||Initial and every 3 months or more frequently, based on ARV regimen or symptoms; check weeks 24-28|
|Chemistries, liver enzymes (LFTs)||Initial and every 3 months or more frequently, based on ARV regimen or symptoms|
If on NRTIs, monitor electrolytes and hepatic enzymes monthly in third trimester
|Fasting lipids and glucose||Initial and as indicated|
|Rh antibody screen||Indicated|
|Pregnancy Specific||Ultrasound||First trimester: confirm gestational age and potential timing for cesarean delivery if necessary|
Second trimester: assess fetal anatomy for women on combination ART during first trimester
|Screening for chromosomal abnormalities||Screen for neural tube and abdominal wall defect, trisomy 21, and trisomy 18; first-trimester testing may include laboratory and ultrasound exam, whereas patients in their second trimester are evaluated by multiple marker screening|
Abnormal result requires further investigation - consider amniocentesis only if abnormality is detected on multiple marker screening or level-2 sonogram and the woman is on suppressive ART (to decrease risk of HIV transmission); voluntary and requires counseling
|Diabetes screening||Consider at 20 weeks; check glucose 1 hour after 50 g glucose load; perform 3-hour glucose tolerance test if screen is abnormal|
If 3-hour test result is abnormal, perform regular glucose monitoring, especially in women taking protease inhibitors (PIs)
|Varicella IgG for those without history of chickenpox or shingles||Initial|
|Screening for syphilis: rapid plasma reagin (RPR) or Venereal Disease Research Laboratory (VDRL)||Initial and during weeks 32-36|
|Consider bacterial vaginosis (BV) screening (BV increases risk of preterm labor)||Week 24-28|
|Screening for streptococcus B (if result is positive, intrapartum chemoprophylaxis is indicated)||Week 32-36|
|Screening with herpes simplex virus-2 serology in high-risk patients is recommended by some experts||Initial|
|Urinalysis and clean-catch urine culture||Initial and as indicated|
|Papanicolaou test||Initial and as indicated (colposcopy is done on pregnant women, but biopsy is avoided; management resumes postpartum, after the 6-week postpartum visit)|
|Hepatitis Serologies||Hepatitis A virus (HAV) antibody (IgG)||Initial|
|Hepatitis B virus (HBV): HBsAg, HBcAb , HBsAb||Initial|
|Hepatitis C virus (HCV) antibody||Initial|
|TB Screening||Tuberculin skin test (purified protein derivative [PPD]), more reliable if CD4 count is >200 cells/µL (induration >5 mm is positive); or interferon-gamma release assay (IGRA); note there is limited experience with IGRAs in pregnant women||Initial|
|Disease Specific||Consider hemoglobin electrophoresis, if anemic or at increased risk of hemoglobinopathies||Initial|
|Serum screening for Tay-Sachs disease - both partners - if at increased risk||Initial|
|Urine toxicology screen||Initial and as indicated|
|Admission Laboratory Tests|
Immunizations and Opportunistic Infection Prophylaxis
Immunizations During Pregnancy
Generally, immunizations should be given before pregnancy, if possible. However, immunizations should be considered during pregnancy when the risk of exposure to an infection is high, the risk of infection to the mother or fetus is high, and the vaccine is unlikely to cause harm. The inactivated influenza virus and Tdap vaccines both meet this criteria and are generally recommended during pregnancy, as are certain others (see Table 3). Some vaccinations (particularly live-virus vaccines such as measles/mumps/rubella and varicella vaccines) are contraindicated, and others should be given only if the anticipated benefit of the vaccination outweighs the risk. Special considerations for immunizations in HIV-infected individuals are discussed in chapter Immunizations for HIV-Infected Adults and Adolescents.
Because vaccinations may cause a transient increase in the HIV viral load and theoretically may increase the risk of perinatal HIV transmission, vaccination should be given after pregnant women are on ART.
|Hepatitis A virus (HAV)||Recommended for susceptible patients at risk of becoming infected, those with chronic HBV or HCV, those traveling to endemic areas, injection drug users, and those in the setting of a community outbreak.|
|Hepatitis B virus (HBV)||Generally recommended for susceptible patients at risk of HBV infection during pregnancy.|
|Human Papilloma Virus (HPV)||Not recommended during pregnancy.|
|Influenza||Inactivated influenza vaccine is recommended for all pregnant women, before or during flu season. Live attenuated vaccines should not be used.|
|Pneumococcus||Generally recommended. Limited data on safety during pregnancy for both the PPSV23 and PCV13 vaccines: no reports of adverse effects with PPSV23; limited experience with PCV13.|
|Tetanus-diphtheria-pertussis (Tdap)||Recommended during each pregnancy. Can be given at any time in pregnancy, but optimally between 27 and 36 weeks' gestation (to maximize maternal antibody response and passive antibody transfer to the infant).|
In addition, family members and caregivers should receive Tdap vaccination.
|Immune globulins |
(for postexposure prophylaxis in susceptible individuals)
|Measles||Recommended after measles exposure.|
|Hepatitis A||Recommended after exposure (close contact or sex partner), or in case of travel to endemic areas.|
|Varicella-zoster virus immune globulin (VariZIG)||Recommended for susceptible individuals after close contact with someone with varicella or herpes zoster (give as soon as possible, and within 10 days of exposure).|
|Hepatitis B immune globulin (HBIG)||Recommended for susceptible individuals after needlestick or sexual exposure to a person with hepatitis B infection.|
Opportunistic Infection Prophylaxis
Some OIs can have an adverse effect on pregnancy. In turn, pregnancy can affect the natural history, presentation, treatment, and significance of some OIs. Women should be monitored carefully for OIs during pregnancy, with special attention given to nonspecific symptoms such as fatigue, back pain, and weight loss, which may be attributable to HIV-related illness rather than to pregnancy. Respiratory symptoms in particular merit rapid, aggressive investigation. Clinicians should follow the most current recommendations of the U.S. Centers for Disease Control and Prevention (CDC), National Institutes of Health, and Infectious Diseases Society of America, Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, which give special consideration to pregnant women for each OI discussed. The indications and recommendations for OI prophylaxis generally should follow the guidelines for adults (see chapter Opportunistic Infection Prophylaxis). However, because of the risks of teratogenicity or harm to the developing fetus, some drugs routinely used for prophylaxis of OIs in nonpregnant adults are contraindicated during the first trimester of pregnancy, whereas others should not be used at any time during pregnancy.
Special Considerations for OI Prophylaxis During Pregnancy
In pregnant women, folate deficiency increases the risk of neural tube defects in the developing fetus. Trimethoprim inhibits the synthesis of metabolically active folic acid and thus increases the risk of folate deficiency and congenital anomalies. Pregnant women, or women who may become pregnant, who are taking trimethoprim-sulfamethoxazole (TMP-SMX, Septra, Bactrim, cotrimoxazole) should be given folate supplementation to reduce the risk of neural tube defects. However, folate also counteracts the activity of TMP, and may compromise the therapeutic efficacy of TMP-SMX.
The recommended dosage of folic acid usually is 0.4 mg/day, but the optimal dosage in women on TMP-SMX is not clear. Some experts recommend higher dosages during the first trimester, when the fetus is at greatest risk for teratogenic effect.
TMP-SMX is the recommended drug for women who require prophylaxis against PCP during pregnancy; alternatives to TPM-SMX during first trimester include aerosolized pentamidine and atovaquone.
Women with HIV infection are more likely than HIV-uninfected women to experience outbreaks of genital herpes. If HSV is transmitted to the infant, neonatal infection can be severe, even if it is detected and treated early. In addition, there is increased genital shedding of HIV in those with active genital HSV lesions though it is not known whether this remains true in women treated with effective ART. Some experts recommend obtaining HSV-2 serologies in a woman whose clinical history is unclear. Treatment for symptomatic HSV infections should be offered during pregnancy, and suppressive therapy should be given to women with frequent recurrences. Suppressive therapy with acyclovir or valacyclovir also should be offered to any woman with an HSV recurrence during pregnancy, starting at 36 weeks' gestation. If a woman has an active outbreak of genital HSV or experiences prodromal symptoms at the time of labor or membrane rupture, delivery by cesarean section is indicated. Prophylaxis for pregnant women who are seropositive for HSV-2 but who do not have a history of genital lesions is not recommended.
Prophylaxis is recommended for any woman with a positive PPD skin test result (≥5 mm induration), a positive IGRA result, or a history of exposure to someone with active tuberculosis, after active disease has been ruled out. Patients receiving isoniazid also should receive pyridoxine to reduce the risk of neurotoxicity.
All HIV-infected persons should be tested for IgG antibodies to Toxoplasma soon after HIV diagnosis, and this should be a part of antenatal testing for pregnant women with HIV infection. Women with a negative IgG titer should be counseled to avoid exposure to Toxoplasma (e.g., by avoiding raw or undercooked meats, unwashed or uncooked vegetables, and cat feces). Women with previous exposure to Toxoplasma (positive IgG titer) should be given prophylaxis during pregnancy, if the CD4 count is <100 cells/µL. For women who require prophylaxis, TMP-SMX is the preferred agent (see considerations for TMP-SMX, above).
HIV-infected pregnant women who have evidence of primary or reactivated Toxoplasma infection should be managed by a specialist.
The current HHS guidelines recommend treating HIV infection in all pregnant women, using the same principles and modalities as used for nonpregnant individuals. HIV-infected pregnant women should receive potent combination ART regimens comprising at least three ARVs. The choice of ARV regimen should be based on what is likely to be optimal for the woman's health, the potential effect on the fetus and infant, resistance test results, the woman's previous experience, if any, with ART, and her stage of pregnancy. ARV resistance testing should be performed before initiating or changing therapy, but should not delay the initiation of ART in late stages of pregnancy. Combination ART in pregnancy should include ZDV or another NRTI with good placental passage. ARV agents with potential teratogenic effects should be avoided in the early weeks of pregnancy (however, efavirenz may be continued during pregnancy, provided the regimen is tolerated and is providing effective virologic control). Women who have very high CD4 cell counts and are taking ART only for the prevention of perinatal transmission may delay initiation of therapy until after the first trimester, though effectiveness in preventing transmission may be decreased. For women already taking ART at the time they become pregnant, the regimen should be reevaluated for its appropriateness during pregnancy to avoid potentially toxic medications and to ensure maximal virologic suppression. Generally, any ART regimen that is effective and tolerated by the woman may be continued during pregnancy. If necessary, the ART regimen may be changed but therapy should continue without interruption. Discontinuation of ART could lead to an increase in viral load, which could result in a decline in immune status and an acceleration of disease progression, thereby increasing the risk of HIV transmission to the fetus.
For further information about ART during pregnancy, see chapter Reducing Maternal-Infant HIV Transmission and the HHS Perinatal ARV Guidelines. The guidelines include recommendations regarding ARV regimens, modes of delivery (vaginal vs. cesarean section), and potential adverse events, as well as a detailed discussion of individual ARV agents. Additionally, the treatment of pregnant women with HIV/HBV coinfection and HIV/HCV coinfection is discussed.
Antiretroviral Pregnancy Registry
To improve tracking of pregnancy-related adverse events and fetal effects, an Antiretroviral Pregnancy Registry has been established as a collaborative project among the pharmaceutical industry, pediatric and obstetric providers, the CDC, and the National Institutes of Health. The registry collects observational data on HIV-infected pregnant women taking ARV medications to determine whether patterns of fetal or neonatal abnormalities occur. Pregnant women taking ARVs can be placed in this confidential follow-up study by calling 800-258-4263, 8:30 a.m. to 5:30 p.m. eastern time; the fax number is 800-800-1052. Information is confidential and patients' names are not used. Providers are encouraged to add to the available information on fetal risk by using this registry at first contact with a pregnant woman receiving ART. More information can be obtained at www.APRegistry.com.
Pregnancy-Specific Complications and Management
Nutrition risk and inadequate weight gain
Maternal nutrition and weight must be monitored throughout the pregnancy. A food diary may be a useful tool in assessing intake, and nutritional counseling is recommended.
Nausea and vomiting
Women with signs of dehydration should be assessed and treated appropriately in collaboration with the obstetrician or nurse/midwife. Any medication used for nausea and vomiting must be assessed for drug-drug interactions with all HIV-related medications the patient is taking.
Pregnancy is a risk factor for hyperglycemia, and women treated with PIs may have an even higher risk of glucose intolerance than other pregnant women and must be monitored carefully. New-onset hyperglycemia and diabetes mellitus, and exacerbation of existing diabetes, all have been reported in patients taking PIs. Clinicians should educate women taking PIs about the symptoms of hyperglycemia and closely monitor glucose levels. Women with HIV-infection should receive standard glucose screening at 24-28 weeks' gestation. Women who were taking a PI-based regimen prior to pregnancy may be screened earlier according to recommendations for women at high risk of glucose intolerance. The newborn should be checked for neonatal hypoglycemia at 1 and 4 hours after birth.
Lactic acidosis is a rare but life-threatening complication that has been reported in pregnant women taking nucleoside reverse transcriptase inhibitors, particularly didanosine and stavudine. The combination of didanosine and stavudine should be avoided during pregnancy. Clinical suspicion of lactic acidosis should be prompted by vague symptoms such as malaise, nausea, or abdominal discomfort or pain. Hyperbilirubinemia
Women taking atazanavir or indinavir frequently develop elevated indirect bilirubin, but it is not known whether treatment during pregnancy exacerbates physiologic hyperbilirubinemia in newborns. Women who are taking indinavir may have an increased risk of nephrolithiasis, but evidence of harm to their newborns has not been demonstrated. Indinavir should be used during pregnancy only when preferred and alternative agents are not acceptable, and it must be boosted with low-dose ritonavir.
Pain management during labor and delivery may be complicated by drug interactions with ARV agents and by the higher medication tolerance in women who have addictions. Additional pain medication may be needed for women with histories of drug use.
Invasive perinatal procedures
The risk of HIV transmission to the fetus during invasive procedures (e.g., amniocentesis, chorionic villus sampling, and percutaneous or umbilical cord blood sampling) must be weighed carefully against the possible benefits of these procedures. Current HHS guidelines suggest that women undergoing such procedures should be on effective ART, preferably with undetectable HIV RNA. The use of fetal scalp electrodes and artificial rupture of membranes should be avoided if possible, and forceps or vacuum extractors and episiotomy should be used only if there are clear obstetric indications.
Because HIV can be transmitted to the infant through breast-feeding, breast-feeding is contraindicated in the United States and other resource-adequate countries where safe replacement feeding is available. Breast-feeding information should be removed from patient educational material pertaining to labor and delivery. Lactation suppression techniques can be used as needed to reduce lactation discomfort. Clinicians should recognize that women in some cultural groups are expected to breast-feed and they may need additional support to use formula rather than breast-feed.
ART should be continued, unless the woman refuses ARVs. Maternal and infant medication adherence must be discussed with the new mother. Adherence barriers for the mother during the postpartum period may be different from those during pregnancy (e.g., because of changes in daily routine, sleep/wake cycles, and meals).
New mothers should be observed carefully for signs of bleeding or infection.
If the mother's glucose tolerance test result was abnormal during pregnancy, she should be reevaluated 6-12 weeks postpartum and should be screened yearly for diabetes.
At the infant's 2-week follow-up visit, the HIV pediatric clinician should address the mother's concerns, screen for postpartum depression, assess adherence to her own and the infant's ARV medications, and ensure follow-up for the 6-week postpartum visit with the obstetric provider and soon thereafter with the primary HIV care provider. These visits provide an opportunity to address the woman's contraceptive needs and options, if this was not done previously (see chapter Health Care of HIV-Infected Women Through the Life Cycle).
Many contraceptive choices are available for HIV-infected women; considerations are discussed in chapter Health Care of HIV-Infected Women Through the Life Cycle. Consistent condom use should be emphasized, and for women who wish to avoid pregnancy a "dual-protection" strategy, condom use plus another method of birth control, should be emphasized. This strategy effectively prevents pregnancy, prevents transmission of HIV to sex partners, and prevents the acquisition of sexually transmitted diseases. It is important to provide women with all contraceptive options including long-acting reversible contraceptive methods such as the intrauterine device and implants.
- Reinforce regularly and clearly the notion that, when the mother cares for herself, she is caring for her infant. Talk with the patient about stress, the importance of adequate mild-to-moderate exercise, and sufficient rest.
- Emphasize that regular prenatal care is extremely important to prevent complications of pregnancy.
- Use of a prenatal vitamin supplement is important, but cannot replace healthy food intake. Develop a plan with the patient for attaining the desired weight gain during pregnancy, while maintaining a healthy nutritional intake.
- Cigarette, alcohol, and drug use contribute to poor maternal nutrition and can harm the developing fetus. Illicit drug use increases the risk of transmitting HIV to the infant. Injection drug use can transmit HBV, HCV, and CMV to the mother and to the baby. Encourage cessation of cigarette, alcohol, and drug use, and offer referrals for treatment, as needed.
- Be sure the woman understands all planned procedures and treatments and understands their potential risks and benefits both to herself and to the fetus.
- Discuss the risks and benefits (to the woman and fetus) of each medication to be taken during pregnancy, including those for which there are limited data on teratogenicity.
- Discuss ART as a benefit to the woman's health and as part of the strategy to reduce the risk of perinatal HIV transmission to the fetus or newborn. Also discuss the effect of ART on reducing risk of HIV transmission to sex partners.
- For women at risk, diligent use of "safer sex" during pregnancy is important for preventing infection with STDs and CMV, which can cause more complications when HIV is present. STDs can harm fetal development and may increase the risk of HIV transmission to the baby. New genital herpes infections during pregnancy can cause severe complications and even death in neonates.
- For women with negative Toxoplasma titers, explain the need to avoid undercooked meat, soil, and cat feces.
- Teach the pregnant woman how to obtain medical attention quickly at the first signs of OI or other complication. Discuss what to watch for and how to get help when emergencies arise in the evenings or on weekends or holidays.
- Help the patient clarify her child care options and support systems for raising a family.
- ACIP Adult Immunization Work Group, Bridges CB, Woods L, et al.; Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older - United States, 2013. MMWR Surveill Summ. 2013 Feb 1;62 Suppl 1:9-19.
- American College of Obstetricians and Gynecologists. Gestational Diabetes Mellitus. ACOG Practice Bulletin No. 137; 2013.
- American College of Obstetricians and Gynecologists. Update on Immunization and Pregnancy: Tetanus, Diphtheria, and Pertussis. ACOG Committee Opinion No. 566; 2013.
- American College of Obstetricians and Gynecologists. Screening for Fetal Chromosomal Abnormalities. ACOG Practice Bulletin No.77; 2007.
- Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 - 31 January 2013. Accessed December 1, 2013.
- Centers for Disease Control and Prevention. Guidelines for Vaccinating Pregnant Women. April 2013. Accessed December 1, 2013.
- Centers for Disease Control and Prevention. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2013-2014. MMWR Recomm Rep. 2013 Sep 20;62(RR-07):1-43.
- Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010. MMWR Recomm Rep. 2010 Dec 17;59(RR-12):1-110.
- Centers for Disease Control and Prevention. Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep. 2013 Feb 22;62(7):131-5.
- Centers for Disease Control and Prevention. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2012 Oct 12;61(40):816-9.
- Ethics Committee of the American Society for Reproductive Medicine. Human immuno-deficiency virus and infertility treatment. Fertil Steril. 2004 Sep;82 Suppl 1:S228-31.
- Kutty P, Rota J, Bellini W, et al. Manual for the Surveillance of Vaccine-Preventable Diseases (6th Edition, 2013). Accessed December 1, 2013.
- Minkoff H. Human immunodeficiency virus infection in pregnancy. Obstet Gynecol. 2003 Apr;101(4):797-810.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Accessed December 1, 2013.
- Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Accessed December 1, 2013.
- U.S. Department of Health and Human Services. A Guide to the Clinical Care of Women with HIV - 2013 Edition. Rockville, MD: U.S. Department of Health and Human Services; 2013. Accessed March 1, 2013.
- U.S. Department of Health and Human Services. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Accessed December 1, 2013.